BioTime, Inc. Share Price Nyse
Equities
US09066L1052
Biotechnology & Medical Research
Sales 2024 * | 12.22M 960M | Sales 2025 * | 5.87M 461M | Capitalization | 198M 15.57B |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.88B | Net income 2025 * | -35M -2.75B | EV / Sales 2024 * | 16.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 33.8 x |
P/E ratio 2024 * |
-8.08
x | P/E ratio 2025 * |
-6.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.57% |
Latest transcript on BioTime, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 13/11/22 |
Chief Operating Officer | - | 31/12/09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 30/06/09 |
Brian Culley
CEO | Chief Executive Officer | 53 | 16/09/18 |
Deborah Andrews
BRD | Director/Board Member | 66 | 10/04/14 |
1st Jan change | Capi. | |
---|---|---|
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |